Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 10,645.64 | 12,792.28 | 11,287.14 | 15,823.68 | 13,266.48 |
| Operating profit | 2,224.04 | 1,730.92 | 1,473.40 | 4,119.82 | 2,685.75 |
| Interest | 182.60 | 114.98 | 16.94 | 28.68 | 95.58 |
| Gross profit | 2,657.50 | 2,049.70 | 2,127.45 | 4,681.00 | 2,848.18 |
| EPS (Rs) | 33.35 | 21.00 | 24.83 | 53.13 | 31.96 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 616.06 | 433.76 | 670.99 | 589.86 | 258.01 |
| Stock adjustment | -116.23 | -466.00 | 45.51 | 2.99 | -229.53 |
| Raw material | 5,761.08 | 7,247.69 | 5,783.93 | 7,215.73 | 6,747.55 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 980.56 | 1,641.88 | 1,600.04 | 1,735.43 | 1,561.47 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,796.19 | 2,637.79 | 2,384.26 | 2,749.71 | 2,501.24 |
| Provisions made | - | - | - | - | - |
| Depreciation | 254.58 | 435.35 | 415.26 | 487.99 | 470.48 |
| Taxation | 502.82 | 383.94 | 182.77 | 1,080.10 | 504.96 |
| Net profit / loss | 1,954.14 | 1,230.41 | 1,454.71 | 3,112.91 | 1,872.74 |
| Extra ordinary item | 54.04 | - | -74.71 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 20.89 | 13.53 | 13.05 | 26.04 | 20.24 |
| GPM (%) | 23.60 | 15.50 | 17.79 | 28.52 | 21.06 |
| NPM (%) | 17.35 | 9.30 | 12.17 | 18.97 | 13.85 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis